

## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 323498777 US Express Mail Label Number

10/08/03 Date of Deposit

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1654

Copeland et al.

Examiner: Jeffrey E. Russel

**APPLICATION NO: 09/808,832** 

FILED: March 15, 2001

FOR: PEPTIDASE-CLEAVABLE, TARGETED ANTINEOPLASTIC

DRUGS AND THEIR THERAPEUTIC USE

Mail Stop: RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## RESPONSE TO ADVISORY ACTION

In response to the Advisory Action mailed on September 4, 2003, please amend the above-identified application as follows:

Amendments to the Specification are show in the Substitute Specification submitted herewith. A clean copy as required under 37 CFR 1.125 is also submitted.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper. As noted in the Advisory Action, Claims 33 and 34 are now listed as canceled and not withdrawn. Additionally, the proposed amendments to the claims have been corrected to show deletions as strike-throughs rather than brackets as required under 37 CFR 1.121. The amendments to the Claims were not included in the Substitute Specification to avoid confusion.

Remarks/Arguments begin on page 25 of this paper.